Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome

NCT04066088 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped PI departure from institution

Conditions

Prader-Willi Syndrome

Interventions

OTHER: Placebo
DRUG: Guanfacine extended release (GXR)

Sponsor

NYU Langone Health

Collaborators

[object Object]